Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $3.1B | $2.7B | $2.1B | $1.7B | $1.3B | $1.1B | $904M | $738M | $564M | $464M | $367M | $264M | $289M | $247M | $211M | $152M | $97M | $66M | $36M | $13M | $4M |
| Bruttoergebnis | $2.2B | $1.9B | $1.4B | $1.2B | $806M | $752M | $582M | $480M | $370M | $277M | $211M | $133M | $143M | $112M | $92M | $67M | $44M | $18M | ($5M) | ($12M) | ($12M) |
| Bruttomarge % | 71.1% | 71.6% | 69.8% | 68.3% | 61.7% | 68.5% | 64.4% | 65.1% | 65.6% | 59.8% | 57.5% | 50.5% | 49.6% | 45.5% | 43.7% | 43.8% | 45.1% | 27.7% | -12.7% | -92.4% | -327.5% |
| Betriebsergebnis (EBIT) | $516M | $474M | $309M | $220M | $38M | $126M | $52M | $50M | $27M | ($7M) | ($11M) | ($49M) | ($12M) | ($29M) | ($36M) | ($42M) | ($39M) | ($59M) | ($89M) | ($54M) | ($35M) |
| Operative Marge % | 16.9% | 17.5% | 14.9% | 13.0% | 2.9% | 11.5% | 5.7% | 6.8% | 4.9% | -1.6% | -2.9% | -18.5% | -4.3% | -11.8% | -17.0% | -27.9% | -39.8% | -89.9% | -247.8% | -402.7% | -945.8% |
| Jahresüberschuss | $376M | $247M | $418M | $206M | $5M | $17M | $7M | $12M | $3M | ($27M) | ($29M) | ($74M) | ($52M) | ($45M) | ($52M) | ($57M) | ($61M) | ($80M) | ($93M) | ($54M) | ($36M) |
| Nettomarge % | 12.3% | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% | 1.6% | 0.6% | -5.8% | -7.9% | -27.9% | -17.8% | -18.2% | -24.5% | -37.5% | -63.1% | -120.5% | -257.3% | -400.4% | -981.4% |
| EBITDA | — | $532M | $424M | $324M | $109M | $140M | $110M | $74M | $43M | $6M | $1M | ($33M) | $0M | ($17M) | ($25M) | ($28M) | ($33M) | ($54M) | ($75M) | ($49M) | ($32M) |
| Ergebnis je Aktie (EPS) | $5.35 | $3.44 | $5.66 | $2.80 | $0.07 | $0.24 | $0.10 | $0.19 | $0.05 | $-0.46 | $-0.50 | $-1.29 | $-0.93 | $-0.83 | $-1.08 | $-1.22 | $-1.54 | $-2.68 | $-3.36 | $-3.21 | $-39.19 |
| Ausstehende Aktien (Mio.) | — | 72M | 74M | 74M | 70M | 69M | 66M | 62M | 61M | 58M | 57M | 57M | 56M | 54M | 48M | 47M | 40M | 30M | 28M | 17M | 1M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für PODD. /companies/us/PODD
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms